Hologic marked a -0.2% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $71.15? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
-
Hologic belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of None and an average price to book (P/B) of None
-
The company's P/B ratio is 3.43
-
Hologic has a trailing 12 month Price to Earnings (P/E) ratio of 38.9 based on its trailing 12 month price to earnings (EPS) of $1.83 per share
-
Its forward P/E ratio is 16.5, based on its forward earnings per share (EPS) of $4.32
-
HOLX has a Price to Earnings Growth (PEG) ratio of 1.79, which shows the company has a fair value when we factor growth into the price to earnings calculus.
-
Over the last four years, Hologic has averaged free cash flows of $1.22 Billion, which on average grew 6.0%
-
HOLX's gross profit margins have averaged 54.0 % over the last four years and during this time they had a growth rate of 8.5 % and a coefficient of variability of None %.
-
Hologic has moved -7.0% over the last year compared to 14.0% for the S&P 500 -- a difference of -21.0%
-
HOLX has an average analyst rating of buy and is -13.02% away from its mean target price of $81.8 per share